Romina Fiorotto, PhD
Associate Professor of Medicine (Digestive Diseases)Cards
About
Research
Publications
2026
Pathophysiology of cystic fibrosis-related liver disease
Palmiotti A, Bertolini A, Fiorotto R. Pathophysiology of cystic fibrosis-related liver disease. Curr Opin Gastroenterol. 2025 Dec 30. doi: 10.1097/MOG.0000000000001151. Epub ahead of print. PMID: 41461020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Pathophysiology of cystic fibrosis-related liver disease
Palmiotti A, Bertolini A, Fiorotto R. Pathophysiology of cystic fibrosis-related liver disease. Current Opinion In Gastroenterology 2025, 42: 83-89. PMID: 41461020, PMCID: PMC12906353, DOI: 10.1097/mog.0000000000001151.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2024
Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice
Bertolini A, Nguyen M, Zehra S, Taleb S, Bauer-Pisani T, Palm N, Strazzabosco M, Fiorotto R. Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice. Journal Of Hepatology 2024, 81: 429-440. PMID: 38554847, PMCID: PMC11347101, DOI: 10.1016/j.jhep.2024.03.041.Peer-Reviewed Original Research
2023
Fibroblasts to hepatocytes: A nonstop flight into cell therapy for liver diseases?
Gouon‐Evans V, Fiorotto R. Fibroblasts to hepatocytes: A nonstop flight into cell therapy for liver diseases? Hepatology 2023, 77: 1469-1471. PMID: 35957526, DOI: 10.1002/hep.32725.Commentaries, Editorials and LettersCell-matrix interactions control biliary organoid polarity, architecture, and differentiation
Fiorotto R, Mariotti V, Taleb S, Zehra S, Nguyen M, Amenduni M, Strazzabosco M. Cell-matrix interactions control biliary organoid polarity, architecture, and differentiation. Hepatology Communications 2023, 7: e0094. PMID: 36972396, PMCID: PMC10503667, DOI: 10.1097/hc9.0000000000000094.Peer-Reviewed Original Research
2022
Molecular determinants of peri‐apical targeting of inositol 1,4,5‐trisphosphate receptor type 3 in cholangiocytes
Rodrigues MA, Gomes DA, Fiorotto R, Guerra MT, Weerachayaphorn J, Bo T, Sessa WC, Strazzabosco M, Nathanson MH. Molecular determinants of peri‐apical targeting of inositol 1,4,5‐trisphosphate receptor type 3 in cholangiocytes. Hepatology Communications 2022, 6: 2748-2764. PMID: 35852334, PMCID: PMC9512452, DOI: 10.1002/hep4.2042.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDysregulation of the Scribble/YAP/β‐catenin axis sustains the fibroinflammatory response in a PKHD1−/− mouse model of congenital hepatic fibrosis
Fabris L, Milani C, Fiorotto R, Mariotti V, Kaffe E, Seller B, Sonzogni A, Strazzabosco M, Cadamuro M. Dysregulation of the Scribble/YAP/β‐catenin axis sustains the fibroinflammatory response in a PKHD1−/− mouse model of congenital hepatic fibrosis. The FASEB Journal 2022, 36: e22364-e22364. PMID: 35593740, PMCID: PMC9150862, DOI: 10.1096/fj.202101924r.Peer-Reviewed Original ResearchBile acids and their receptors: modulators and therapeutic targets in liver inflammation
Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Seminars In Immunopathology 2022, 44: 547-564. PMID: 35415765, PMCID: PMC9256560, DOI: 10.1007/s00281-022-00935-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Novel approaches to liver disease diagnosis and modeling
Oliveira AG, Fiorotto R. Novel approaches to liver disease diagnosis and modeling. Translational Gastroenterology And Hepatology 2021, 6: 19-19. PMID: 33824923, PMCID: PMC7829068, DOI: 10.21037/tgh-20-109.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNew insights on the role of vascular endothelial growth factor in biliary pathophysiology
Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Reports 2021, 3: 100251. PMID: 34151244, PMCID: PMC8189933, DOI: 10.1016/j.jhepr.2021.100251.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Clinical Trials
Current Trials
Screening In Anticipation of Future Research
IRB ID2000021443RoleSub InvestigatorPrimary Completion Date12/31/2022Recruiting ParticipantsGenderBothAge2 years - 17 years
Academic Achievements & Community Involvement
News & Links
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States